SCIENTISTS have a developed a “game-changing” new “super test” that can diagnose prostate cancer with 96 per cent accuracy.
Olympic cycling legend Sir Chris Hoy – who revealed he had terminal prostate cancer last year – has “wholeheartedly welcomed” the test after calling for men to get access to earlier and more accurate screening.



The test, developed by EDX Medical, can spot cancerous cells and signs of early and late-stage cancer, as well as the disease’s sub-type and whether it’s slow or aggressive.
Scientists at the digital diagnostic group say their tool is more accurate than blood tests currently offered by the NHS, known as the PSA test.
The PSA test checks for levels of prostate specific antigen in the blood – high levels can show that someone has prostate cancer, but it can also indicate other non-cancerous conditions like an enlarged prostate.
EDX Medical said it’s test measures “more than a hundred clinically validated biomarkers” – whereas current tools rely on “up to 20 biomarkers”.
Blood and urine samples are taken and sent off to a lab, where they’re analysed by scientists and an AI algorithm.
The test then takes into account PSA levels in combination with biomarkers and genetic factors to make it more accurate.
The analysis assesses specific proteins in the samples and any DNA mutations, the company said.
By compiling all of this data and using AI to sift through it, people who have prostate cancer but no symptoms are more likely to be diagnosed earlier.
EDX claimed this method can detect prostate cancer with 96 to 99 per cent accuracy across different ages and ethnic groups, whereas current testing – involving PSAs and biopsies – can be only 50 per cent accurate.
Prof Sir Chris Evans, founder and chief scientific officer of EDX Medical, described the test as “truly game-changing”, saying it could be “transformative in tackling prostate cancer in men who may have no idea if anything is wrong with them”.
He added that it would enable earlier detection and better prediction of risk, for example, because of someone’s genetics, allowing for more personalised treatment plans.
Sir Chris hailed the test, saying: “I now know there is a need for better and more accurate prostate cancer screening tests and I wholeheartedly welcome this initiative.”
The Olympic legend has previously suggested men should get prostate checks in their forties, after being diagnosed with incurable cancer aged just 48.
A “little” pain in his shoulder was the only sign of the Olympic legend’s incurable cancer, which had spread from his prostate to his bones.

His statement that it was a “no-brainer” to offer prostate cancer testing to men below the current standard age of 50 prompted Health Secretary Wes Streeting to announce the Government was looking into the matter.
The NHS is now set to review its guidance for prostate cancer testing.
In the UK, more than 50,000 mean are diagnosed with prostate cancer every year and over 12,000 men lose their lives to the disease.
According to Prostate Cancer UK, as many as one in eight men will be diagnosed with it in their lifetime – with black men, over 50s and people with a family history of prostate cancer most at risk.
What is prostate cancer?
Prostate cancer affects a small, walnut shaped gland that sits underneath the bladder and surrounds the urethra – the tube carrying pee outside the body.
It usually grows bigger as you get older.
The prostate’s main job is to help make semen – the fluid that carries sperm.
Most men with early prostate cancer don’t have any signs or symptoms – that’s why it’s important to know about your risk.
Possible symptoms include:
- Difficulty starting to urinate or emptying your bladder
- A weak flow when you urinate
- A feeling that your bladder hasn’t emptied properly
- Dribbling urine after you finish urinating
- Needing to urinate more often than usual, especially at night
- A sudden need to urinate – you may sometimes leak urine before you get to the toilet
If you do notice changes in the way you urinate, this is more likely to be a sign of an enlarged prostate, which is very common and non-cancerous.
But it’s still a good idea to get it checked out.
In the UK, about one in eight men will be diagnosed with prostate cancer in their lifetime.
Some factors may mean you’re more likely to get it.
This includes:
- Getting older – it mainly affects men aged 50 or over
- Having a family history of prostate cancer
- Being Black
If you have any of these risk factors or if you have any symptoms, speak to your GP.
They can talk to you about your risk, and about the tests that are used to diagnose prostate cancer.
Source: Prostate Cancer UK
Rio Ferdinand, former Manchester United and England captain, whose mother and first wife Rebecca died of cancer, said: “Those of us who have lost a loved one to cancer and have campaigned for research and more awareness know full well the need for better and earlier testing across a range of cancers.
“Ethnic minority men not only have twice the risk of getting prostate cancer, they also have higher rates of stage 3 and 4 and more aggressive cancer.
“We know if it can be caught early these men can be mostly cured, but it’s not, and too many men are dying unnecessarily.”
Andy Taylor, guitarist with Duran Duran who was diagnosed with prostate cancer at 55, also responded to news about EDX’s test, saying: “To know your prostate cancer status, stage and type and all your genetics when you were unaware there was a problem at all is a life saver and game-changer.”
The company will be seeking regulatory approval this year in both the UK and US before rolling out the product privately at the start of 2026.
It will then also make an application for it to be used on the NHS, the Telegraph reported.
It’s not the only prostate cancer screening test in development.
Imperial College London is leading a trial backed by Prostate Cancer UK to assess multiple different types of tests to identify what is the best for the NHS to use moving forward.
Prostate Cancer UK said there were “several emerging tests in development which show great promise”.
Simon Grieveson, the assistant director of research at Prostate Cancer UK, told the Telegraph: “We very much welcome advancements that may lead to more accurate and earlier diagnoses; however, many of these tests are still very early in their development and require robust testing in clinical trials before we can know with any certainty just how useful they may be.”
He said the £42 million TRANSFORM trial run at Imperial College would “investigate the best ways to screen men for prostate cancer, including looking at an individual’s genetic risk of prostate cancer”.
“We will also be establishing a vast resource of patient samples and MRI scans which will be hugely valuable in further developing and validating these novel emerging tests for the future,” he added.
Last year, charity Prostate Cancer Research called for a national prostate cancer screening programme to be rolled out across the UK.
Under such a programme, men would be checked for the disease between the ages of 50 and 69, while those at higher risk would get called in for tests from the age of 45, the charity’s head Oliver Kemp said.
There are currently national screening programmes in place to spot breast and bowel cancer, but none for prostate cancer.